April 2, 2021 – Pfizer (New York, NY) and BioNTech (Mainz, Germany) updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their Phase 3 study from March 13, showing the Pfizer BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective against COVID-19, measured seven days through up to six months after the second dose. The vaccine was 100% effective against severe disease as defined by the CDC and 95.3% effective against severe COVID-19 as defined by the FDA.